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Abstract
Background—Giardiasis, the most common enteric parasitic infection in the United States, 
causes an estimated 1.2 million episodes of illness annually. Published clinical recommendations 
include readily available Giardia-specific diagnostic testing and antiparasitic drugs. We 
investigated sequences of giardiasis diagnostic and treatment events using MarketScan, a large 
health insurance claims database.
Methods—We created a longitudinal cohort of 2995 persons diagnosed with giardiasis 
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 
007.1) from 2006 to 2010, and analyzed claims occurring 90 days before to 90 days after initial 
diagnosis. We evaluated differences in number and sequence of visits, diagnostic tests, and 
prescriptions by age group (children 1–17 years, adults 18–64 years) using χ2 tests and data 
visualization software.
Results—Among 2995 patients (212 433 claims), 18% had a Giardia-specific test followed by or 
concurrent with an effective antiparasitic drug, without ineffective antibiotics. Almost two-thirds 
of patients had an antiparasitic and 27% had an antibiotic during the study window. Compared 
with children, adults more often had ≥3 visits before diagnosis (19% vs 15%; P = .02). Adults 
were also less likely to have a Giardia-specific diagnostic test (48% vs 58%; P < .001) and more 
likely to have an antibiotic prescription (28% vs 25%; P = .04). When Giardia-specific tests and 
antiparasitic and antibiotic prescriptions were examined, pediatric clinical event sequences most 
frequently began with a Giardia-specific test, whereas adult sequences most frequently began with 
an antiparasitic prescription.
Correspondence: K. Beer, Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and 
Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329 (kbeer@cdc.gov). 
Disclaimer. The opinions expressed by authors contributing to this article do not necessarily refect the opinions of the Centers for 
Disease Control and Prevention.
Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Supplementary Data: Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the 
authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or 
comments should be addressed to the corresponding author.
HHS Public Access
Author manuscript
Clin Infect Dis. Author manuscript; available in PMC 2018 May 01.
Published in final edited form as:













Conclusions—Giardiasis care infrequently follows all aspects of clinical recommendations. 
Multiple differences between pediatric and adult care, despite age-agnostic recommendations, 
suggest opportunities for provider education or tailored guidance.
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Giardiasis, the disease caused by the parasite Giardia intestinalis (also known as Giardia 
duodenalis or Giardia lamblia), is the most frequently reported human intestinal parasitic 
infection in the United States [1, 2]. With a burden of illness similar to that of nontyphoidal 
Salmonella infections, Giardia causes an estimated 1.2 million episodes of illness annually 
with the highest incidence among children aged 1–9 years [1–3]. Giardia-related 
hospitalizations in the United States cost an estimated $34 million per year [3]. Although 
giardiasis is frequently reported among travelers returning from endemic areas, only 7%–8% 
of US giardiasis cases are travel-associated [2, 4, 5].
Giardia parasite transmission occurs through ingestion of fecally contaminated food or 
water, or through person-to-person contact [6, 7]. Symptoms include prolonged diarrhea, 
abdominal pain, malabsorption, bloating, dehydration, and weight loss. Parasites are shed 
intermittently in feces, and intermittently symptomatic or asymptomatic infections occur 
frequently [8, 9]. Acute giardiasis is disruptive to daily living and can lead to dehydration, 
with children at greater risk of severe dehydration than adults [10]. Following acute 
infection, giardiasis might also lead to long-term chronic disease, including irritable bowel 
syndrome [11, 12].
Current giardiasis diagnostic and treatment recommendations include guidance on 
diagnostic testing and appropriate medications [13, 14]. Several stool-based assays can 
identify Giardia infection, including the ova and parasites microscopy test, and Giardia-
specific enzyme immunoassay, indirect fluorescent assay, and direct fluorescent antibody 
assay. Because Giardia parasites are shed in stool only intermittently, collecting 3 stool 
samples on 3 different days is recommended to maximize diagnostic sensitivity [15]. 
Increasingly, highly sensitive molecular diagnostics are also used. Multiple antiparasitic 
drugs are effective against Giardia, including metronidazole, tinidazole, and nitazoxanide; 
metronidazole and tinidazole are the first-line treatments in the United States [14, 16].
Despite being the most common human intestinal parasitic infection in the United States, 
basic information on giardiasis care and treatment practices is lacking. Some previous 
studies suggest the occurrence of delayed diagnosis of giardiasis (measured as time from 
symptom onset to diagnosis) and inefective treatment with antibiotics. In a US study of 290 
individuals with confirmed giardiasis from 2 states with active laboratory-based surveillance, 
27% were enrolled >6 weeks after their reported symptom onset date [17]. In the same 
study, 10% of patients reported receiving antibiotics, such as ciprofloxacin, which are 
ineffective against Giardia. These data suggest the possibility that delays in giardiasis 
diagnosis and ineffective treatment occur widely. One explanation for these findings is low 
index of suspicion of giardiasis, which causes nonspecific symptoms (eg, diarrhea) common 
to many enteric diseases. In a survey of 1000 pediatricians, only 10% indicated they would 
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suspect parasites in a patient with persistent diarrhea lasting more than 1–2 weeks [18]. If 
Giardia is suspected, specific tests must be ordered because routine bacterial stool cultures 
will not detect the parasite [15]. Therefore, multiple potential areas exist for improvement in 
the diagnosis and treatment of giardiasis in the United States.
Here, we present an analysis of clinic visits for Giardia-related symptoms and diagnoses, 
diagnostic tests, and drug prescriptions from 2006 to 2010 among a giardiasis patient cohort 
(N = 2995), created using a large US health insurance claims database.
Methods
Data Source
We used insurance claims contained in the MarketScan Commercial Claims and Encounters 
database (Truven Health Analytics, Ann Arbor, Michigan), from 2006 to 2010. The database 
contains insurance billing data for patient visits (doctors' office and emergency department), 
hospital stays, diagnostic tests and procedures, and prescription medication for >143 million 
persons in the United States covered by employer-sponsored private health insurance 
(employees, retirees under age 65, former employees, and spouses/partners and dependents 
of these individuals) [19]. Because MarketScan contains de-identified, preexisting insurance 
billing records, and because no interaction or intervention with human subjects occurred and 
no personally identifiable information was used, collected, or transmitted, this analysis was 
not considered human subjects research (as defined in the US Code of Federal Regulations, 
Title 45 Part 46), and therefore was not subject to review by the Centers for Disease Control 
and Prevention (CDC) institutional review board.
Cohort Construction
We constructed a cohort of persons with at least 1 outpatient visit for giardiasis, defined as 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
code 007.1, with initial giardiasis diagnosis occurring from 1 January 2006 through 31 
December 2010. Of 80 million persons enrolled during that time period, 6056 had at least 1 
giardiasis diagnosis. Of these, we excluded 3061 for 1 or more of the following reasons that 
would lead to incomplete data: hospital stay (prescription drugs are not recorded in database 
during hospital stays; n = 390), gaps in enrollment in a MarketScan insurance plan (n = 
374), no evidence of prescription coverage (n = 1270), and enrollments of <90 days before 
or after initial diagnosis (n = 1948).
The analysis was limited to claims dated from 90 days before to 90 days after each patient's 
first giardiasis diagnosis (ie, first clinic visit with a giardiasis diagnosis code), creating a 
180-day study window for each patient.
Variable Definitions and Analytical Approach
We focused on a set of diagnosis codes, procedures codes, and prescription drugs likely to 
be associated with an episode of giardiasis (Supplementary Table 1). We included insurance 
claims for patient visits with a diagnosis code for giardiasis (ICD-9-CM code 007.1) or other 
gastrointestinal (GI) illnesses or problems (ICD-9-CM codes 001–009, 520–529, 787, and 
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792.1). We specifically identified visits with a diagnosis of Shigella, Salmonella, 
Campylobacter, Escherichia coli, Cryptosporidium, Clostridium difficile, or norovirus 
infection, to assess alternate infectious diagnoses or coinfections. We also included 
insurance claims for diagnostic tests used to diagnose giardiasis or other gastrointestinal 
illnesses or problems [20]. Use of molecular assays (eg, film array– and bead-based assays) 
was likely uncommon in the study time period. Among prescription drug claims, we 
included prescriptions for systemic antiparasitic drugs (drugs effective against Giardia: 
albendazole, furazolidone, metronidazole, nita-zoxanide, ornidazole, paromomycin sulfate, 
quinacrine, secnidazole and tinidazole) and systemic antibiotics (drugs ineffective against 
Giardia: cephalosporins, erythromycin and macrolides, penicillins, quinolones, 
sulfonamides, and miscellaneous antibiotics). The MarketScan database contains the date a 
prescription was filled but does not indicate which healthcare encounter was associated with 
the prescription. Additionally, medications can be prescribed for a variety of indications. For 
example, metronidazole is often prescribed for giardiasis but is also indicated for treatment 
of bacterial vaginosis, trichomoniasis, amebiasis, and anaerobic bacterial infections [21]. 
Thus, we included only prescriptions filled within the 7 days before to 30 days after a visit 
involving abdominal pain, diarrhea, or giardiasis. These visit-associated prescriptions [22] 
comprised 96% of total prescriptions during the 180-day study window.
We grouped these diagnosis codes, diagnostic test codes, and prescriptions into the 
following giardiasis-related “event” types: patient visits with a giardiasis diagnosis, visits for 
GI symptoms, Giardia-specific diagnostic tests, diagnostic tests for other GI-related illnesses 
or problems, antiparasitic prescriptions, and antibiotic prescriptions. We considered the 
timing of each event and identified the first and last date of each event type (Supplementary 
Table 2).
We then assessed the frequency of each event type, and because we hypothesized that 
giardiasis care experiences might differ for pediatric and adult patients, we stratified 
analyses by age at first giardiasis diagnosis (0–17 years, 18–64 years). We also evaluated 
differences in diagnostic testing and prescriptions by sex and US census region of residence 
(Northeast, South, Midwest, and West). We evaluated statistical differences in proportions 
using χ2 test, or Fisher exact test when expected cell counts were <5. Data management and 
analyses were conducted using SAS software version 9.3 (SAS Institute, Cary, North 
Carolina) and R version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria).
We then used the EventFlow data visualization tool (University of Maryland, Human-
Computer Interaction Lab; http://hcil.umd.edu/eventfow) to visually inspect the data and 
identify clinically relevant temporal event sequences [23–25]. EventFlow aggregates 
longitudinal data by grouping individuals with similar sequences of events and representing 
these groups with color-coded vertical bars in a single graphic display that summarizes 
information on event order, time between events, and frequency of particular event 
sequences (Supplementary Figure 1). Each row in an EventFlow figure represents 1 patient's 
sequence of events during a period of time. The height of each bar is proportional to the 
number of records with that sequence, and its horizontal position is determined by the 
median time between events. Groups of sequences with the same preceding event are sorted 
by the number of records in each group. The sequence groups are shown from top to bottom 
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in descending order of number of patients per group. A brief demonstration video illustrates 
the process (http://go.umd.edu/eventfow-overview). We also used EventFlow to search the 
patient event sequences for signatures of giardiasis care and treatment recommendations. 
Specifically, we queried for sequences containing a Giardia-specific test, followed by or 
concurrent with an antiparasitic prescription, and without any antibiotic prescription.
Results
Within the cohort of 2995 giardiasis patients, half were female, and 30% were aged ≤17 
years at diagnosis (Table 1).
Half of all patients (50%; n = 1496) had ≥3 clinic visits with codes for GI symptoms or 
giardiasis, and adults were more likely to have ≥3 visits compared with children (52% vs 
46%; Table 2). Preceding their initial visit with a giardiasis diagnosis, 18% of all patients (n 
= 535) had ≥3 visits for GI symptoms, and adults were more likely than children (19% vs 
15%) to have ≥3 GI symptom visits before receiving a diagnosis. Overall, 22% of patients (n 
= 657) waited >30 days from their first GI symptom visit to their first visit with a giardiasis 
diagnosis, and 40% (n = 1192) waited >30 days from first to last GI symptom or giardiasis 
diagnosis visit during the study window. These intervals did not vary by age group.
More than half of patients (62%; n = 1853) had a diagnostic test for gastrointestinal illnesses 
or problems, including Giardia (Table 3). Among these, 82% (n = 1515) had a Giardia-
specific test. Pediatric patients were significantly more likely than adults to have had at least 
1 Giardia-specific test (58% vs 48%).
Most patients (72%; n = 2142) had prescriptions for either antiparasitic or antibiotic drugs. 
About two-thirds (64%; n = 1906) had an antiparasitic drug (Table 4). Adult patients were 
significantly more likely than pediatric patients to have an antiparasitic prescription of any 
kind (68% vs 53%). Metronidazole was most common overall, but pediatric patients were 
significantly more likely to have nitazoxanide compared with adults (23% vs 5%). Twenty-
seven percent of all patients (816/2995) had a systemic antibiotic ineffective against Giardia.
We quantified comorbid GI diagnoses and Giardia-specific tests and drugs, to evaluate the 
validity of the giardiasis diagnosis used to define the cohort. Comorbid diagnoses of 
Shigella, Salmonella, Campylobacter, E. coli, Cryptosporidium, C. diffcile, or norovirus 
infection were uncommon (2.2%), and most patients (83%) had either a Giardia-specific 
diagnostic test or a prescription appropriate for giardiasis.
The proportion of patients receiving a Giardia-specific diagnostic test varied from 44% in 
the South to 60% in the Northeast (P < .001), proportions of patients with antiparasitic 
prescriptions varied from 55% in the Northeast to 68% in the South (P < .001), and 
antibiotic prescriptions varied from 22% in the Northeast to 30% in the South (P = .004) (not 
shown).
Temporal event sequences analyzed in EventFlow revealed that the giardiasis care and 
treatment event sequence is variable, with 1010 (34%) unique event sequences represented 
among the entire cohort. In total, patients had a median of 5 events (eg, visits, tests or 
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prescriptions; range, 1–47) during the 180-day study window. Median elapsed time from 
first to last event was 23 days (range, 0–196 days) (Supplementary Figure 2). The first event 
recorded for most patients was a visit for a GI-related symptom (61%); for 22% of patients, 
the first event was an antiparasitic prescription. For 28% of patients, the first event was 
either an antiparasitic or antibiotic prescription (SupplementaryTable 2).
Eighteen percent (n = 541) of patient event sequences included a Giardia-specific test 
followed by or concurrent with an antiparasitic prescription, with no antibiotic prescription, 
and thus were consistent with published recommendations. Event sequences differed 
between pediatric and adult patients. When Giardia-specific tests and antiparasitic and 
antibiotic prescriptions were examined, event sequences for pediatric patients most 
frequently began with a Giardia-specific test, whereas event sequences for adult patients 
most frequently began with an antiparasitic prescription (Figure 1).
Discussion
Using a large insurance claims database to characterize giardiasis diagnosis and treatment in 
the United States, we showed that the entire clinical event sequence takes >3 weeks for most 
patients, and often requires multiple visits, procedures, and prescriptions. Furthermore, we 
found that pediatric giardiasis care differs substantially from adult care, even though 
treatment recommendations do not differ by age group. Our results suggest that giardiasis 
diagnosis can be time-consuming and potentially costly for patients and clinicians, and that 
many patients do not have recommended diagnostics or drugs.
Our analysis also revealed that the giardiasis diagnosis and treatment process is highly 
variable and sometimes at odds with established guidelines. Nearly 40% of patients 
experienced >30 days between their first and last physician visit for GI symptoms, and 22% 
experienced ≥30 days before their first visit with a giardiasis diagnosis code. This finding is 
consistent with a previous study of laboratory-confirmed giardiasis patients in which 27% of 
laboratory-confirmed cases could not be enrolled until >6 weeks after their reported onset, 
suggesting a protracted (delayed) diagnostic process [17]. Only 18% of patients had a 
Giardia-specific test followed by an antiparasitic medication effective against giardiasis, 
without an ineffective antibiotic, a sequence we examined based on consistency with current 
recommendations. On the other hand, 27% of patients had an antibiotic ineffective against 
Giardia at some point in the study window, which is nearly 3-fold higher than a previous 
estimate [17]. The low consistency with recommended practice was surprising, in light of 
the availability of multiple sufffciently sensitive diagnostic testing options, effective 
antiparasitic drugs, and published guidance that suggests the use of such tests and drugs as 
best practices [13, 14, 26, 27]. However, the finding that 30% of patients had a visit-
associated antiparasitic or antibiotic prescription as their first event suggests that, for some 
clinicians and patients, the presumed speed and ease of empiric treatment might outweigh 
the potential discomfort and expense of additional diagnostic visits. Empiric treatment 
carries the risk of patients taking unnecessary and ineffective medications that might 
contribute to the development of antibiotic resistance, and empirically treating contacts of 
laboratory-confirmed cases may increase the number of probable vs confirmed cases notified 
to CDC and could result in an underestimated national disease burden. Rapid molecular 
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assays, while unlikely to be used in MarketScan during this study period, could increase the 
use and sensitivity of gastroenteritis diagnostics, and reduce apparent empirical treatment.
We found that pediatric patients had more Giardia-specific tests, but fewer prescriptions, 
than adults. Moreover, data visualization using EventFlow showed that age-specific event 
sequences had distinct hallmarks, when the subset of diagnostic tests and prescription events 
were analyzed: Children often had 1 or more tests preceding prescriptions, while a majority 
of adults began with antiparasitic or antibiotic prescriptions. Together, these observations 
suggest that children tend to have a more thorough workup, while adults have more frequent 
prescriptions without preceding diagnostic tests, suggesting empiric treatment. Although 
current giardiasis care recommendations are not age-specific, differences between pediatric 
and adult giardiasis care are not surprising. The incidence of giardiasis (and other 
gastroenteritis) is not uniform across the age spectrum in the United States. Giardiasis 
incidence is highest in children [1], and a recent study of laboratory-tested acute 
gastroenteritis patients showed that likelihood of detecting any GI pathogen in feces 
decreases significantly with age [29], suggesting that pediatric practitioners might suspect 
giardiasis (or other pathogenic etiologies) more often, and be more familiar with testing and 
treatment methods compared with adult practitioners. As expected, the majority of 
antiparasitic prescriptions for all patients were for metronidazole. Tat pediatric patients had 
more nitazoxanide prescriptions than adult patients might be explained by nitazoxanide but 
not metronidazole availability in an oral suspension.
Although administrative data such as insurance claims records can provide large amounts of 
data at comparatively low cost to investigators, we acknowledge several limitations in these 
data. First, our cohort represents giardiasis patients who were commercially insured for >6 
months and might have different clinical experiences from the uninsured or briefly insured, 
or persons with Medicaid coverage. In particular, the uninsured might seek to minimize 
visits and diagnostic testing. Second, the structure of the medical and prescription claims 
databases did not allow us to precisely assign prescriptions to the disease or symptom for 
which they were prescribed. To restrict our analyses to prescriptions associated with 
giardiasis, we only included prescriptions filled from 7 days preceding to 30 days following 
a visit for giardiasis, abdominal pain, or diarrhea [22]. Finally, giardiasis diagnoses could not 
be validated with medical records, and while the database contains insurance claims for 
diagnostic tests, it is unknown whether separate tests involve separately collected specimens 
or what proportion of tests had confirmed positive results. Administrative data have been 
validated for irritable bowel syndrome and other diseases [30–33], but have not been used 
previously for giardiasis. However, an alternate infectious diagnosis was identified in only 
2.2% of patients in our cohort, and 83% of patients had a Giardia-specific test or 
antiparasitic prescription, increasing our confidence that most patients in our cohort indeed 
had giardiasis.
In this comprehensive characterization of the giardiasis clinical care experience within a 
large cohort of commercially insured patients, we found that receiving all aspects of 
recommended care—including a diagnostic test, a prescription for antiparasitic medication, 
and no prescription for ineffective antibiotics—was relatively rare. Valid reasons may exist 
for these deviations from recommendations in many instances, although lack of awareness 
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might be a factor. Qualitative studies exploring clinicians' rationale for giardiasis-related 
clinical decisions would be useful for planning public health messaging and clinician 
education. We also identified substantial differences in pediatric and adult giardiasis care, 
with children more often receiving diagnostic testing and adults more often starting care 
with a prescription. Although current clinical guidance does not differ by age, 
acknowledging practical reasons for age-group differences might present opportunities for 
revised public health guidance that better refects the unique scenarios presented by adults 
and children with gastrointestinal illnesses. Finally, this study contributes a greater 
understanding of real-world giardiasis care, which could inform future studies of the 
consequences of missing or ineffective treatment.
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EventFlow plots of pediatric (A) and adult (B) giardiasis event sequences. All sequences 
(rows) are aggregated by event order, with each patient's first event during the study window 
represented by a vertical bar at the far left. Bar height represents the proportion of patients 
with a given sequence, and bar shading represents event type. Distance between bars is 
equivalent to median time in days between any 2 events. Three Giardia-specific event types 
are shown: Giardia-specific tests (black), antiparasitic prescriptions (dark gray), and 
antibiotic prescriptions (light gray). Most but not all cohort patients had at least 1 of these 3 
events. Therefore, plots show pediatric (n = 782; 86%) and adult (n = 1808; 87%) sequences 
containing any of the 3 events. Time from first event (horizontal axis) is truncated to 60 days 
for clarity; 72% of all sequences had total elapsed time of ≤60 days. Starting from the left of 
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the panels, we saw that more pediatric vs adult sequences started with a Giardia-specific test 
(black bars) and included multiple consecutive tests, whereas adult sequences were more 
likely to begin with an antiparasitic drug (dark gray bars).
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Table 1
Giardiasis Outpatient Cohort Characteristics (N = 2995) in the MarketScan National 
Insurance Claims Database, 2006–2010
Characteristic No. (%)
Female sex 1499 (50.1)
Age, y
 0–17 910 (30.4)
 18–34 612 (20.4)
 35–44 537 (17.9)
 45–54 515 (17.2)
 55–64 421 (14.1)
US Census Region of residence
 South 1297 (43.3)
 West 774 (25.8)
 Midwest 546 (18.2)
 Northeast 361 (12.1)
 Unknown 17 (0.6)
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